Loading clinical trials...

Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease

Randomized, Multicenter, Double-blind, Double-dummy, Parallel-Group Study With an Open-label Extension Phase to Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease

NCT01539031•Eisai Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to compare 23 mg donepezil sustained release to the currently marketed formulation of 10 mg donepezil immediate release in patients with severe Alzheimer's disease.

Eligibility

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis: diagnostic evidence of probable Alzheimer's disease (AD) consistent with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR) 290.00 or 290.10
•Mini Mental State Examination (MMSE) less than or equal to 12 and greater than or equal to1 inclusive, at Screening
•SIB less than or equal to 90 and greater than or equal to10 at both Screening and Baseline
•No evidence of focal disease to account for dementia on any cranial image (magnetic resonance imaging \[MRI\] or computed tomography \[CT\]).
•Subject age range: male and female subjects greater than or equal to 50 years of age inclusive
•Outpatients (patients in nursing homes are eligible)
•The subject must have a caregiver who will provide informed consent separately for his/her own participation in the study, who will have regular contact with the subject.
•Stable donepezil dose of 10 mg, taken as a single, daily dose for greater than or equal to 3 months prior to the Screening visit
•Subjects who can swallow hole tablets, as tablets should not be broken or crushed
•Comorbid medical conditions must be clinically stable prior to Screening unless otherwise specified.
+2 more criteria

Exclusion Criteria

•Subjects with a known history of disorders that affect cognition or the ability to assess cognition but are distinguishable from AD
•Subjects with dementia complicated by other organic disease or AD with delirium
•Known hypersensitivity to donepezil or piperidine derivatives, or to any of the excipients in the study drug formulation

Locations (54)

Anjo, Aichi-ken, Japan

Ōbu, Aichi-ken, Japan

Toyoake, Aichi-ken, Japan

Chikushi, Fukuoka, Japan

Kitakyushu, Fukuoka, Japan

Fukuoka, Gunma, Japan

Miyoshi, Hiroshima, Japan

Ōtake, Hiroshima, Japan

Amagasaki, Hyōgo, Japan

Himeji, Hyōgo, Japan

Key Dates

Start Date

March 1, 2012

Primary Completion Date

January 1, 2015

Completion Date

March 1, 2015

Last Updated

June 18, 2023

Enrollment

351

ACTUAL participants

Conditions

Alzheimer's Type Dementia

Interventions

E2020

DRUG

E2020

DRUG